What is the latest on Capricor Therapeutics' Deramiocel and its FDA journey

Related Articles

What is Seaport Therapeutics and Why is its IPO Significant

6 months ago

What Does the FDA's NDA Acceptance Mean for Mineralys Therapeutics

6 months ago

Is Veradigm (MDRX) Poised for a Comeback After Its Tumultuous Journey

6 months ago

What Does Ultragenyx's Latest FDA Clearance Mean for Investors

7 months ago

Category

You may also like

Stock News•2 months ago

Why Is Capricor Therapeutics Stock Trading Higher on Monday?

Capricor Therapeutics (NASDAQ:CAPR) shares rose Monday after the FDA continued its review of deramiocel, a potential Duchenne muscular dystrophy therapy. The update signals ongoing regulatory progress...

CAPR

Share

Stock News•2 months ago

Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Capricor Therapeutics reported ~$238M in cash as of June 30, 2026, while its deramiocel BLA remains under FDA review. HOPE-3 Phase 3 results published in The Lancet showed the primary upper limb endpo...

CAPR

Share

Stock News•3 months ago

FDA panel votes against Capricor's Duchenne heart disease therapy

Capricor Therapeutics' deramiocel faced an FDA panel vote against its benefits for Duchenne cardiomyopathy, a setback for the rare-disease cell therapy.

CAPR

Share